Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst

Benzinga_recent_news12-13

Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics designed to suppress hunger for Prader-Willi Syndrome (PWS) and metabolic...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591686624?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-13 03:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591686624","market":"us","top_or_hot":-1,"title":"Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst","media":"Benzinga_recent_news","content":"<div>\n<p>Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics designed to suppress hunger for Prader-Willi Syndrome (PWS) and metabolic...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-13 03:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics designed to suppress hunger for Prader-Willi Syndrome (PWS) and metabolic...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AARD","symbol_name":"Aardvark Therapeutics","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst","article_id":"2591686624","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591686624","pubTimestamp":1765566240,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Aardvark Therapeutics gains an Outperform rating as its Phase 3 PWS trial progresses and analysts point to large market potential for ARD-101 and ARD-201.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AARD":"Aardvark Therapeutics","PWS":"Pacer WealthShield ETF"},"translate_title":"分析师：Aardvark的饥饿抑制候选药物可能会解决100亿美元的巨大市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AARD":1,"PWS":1},"content_text":"Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics designed to suppress hunger for Prader-Willi Syndrome (PWS) and metabolic diseases.\nLead compound, oral ARD-101, is in Phase 3 clinical development for hyperphagia associated with PWS, a rare disease characterized by insatiable hunger.\nOn Wednesday, Aardvark Therapeutics dosed the first patient in Australia in its Phase 3 HERO clinical trial assessing ARD-101.\nAdditionally, regulatory clearance for enrollment by clinical trial sites in Canada and the United Kingdom has also been received.\nAlso Read: Aardvark’s Hunger-Suppressing Drug Promises Weight Loss Without GI Distress\nWilliam Blair initiated coverage on Aardvark Therapeutics with an Outperform rating.\nBased on strong enrollment in the U.S. and continued progress in advancing the clinical trial internationally, the clinical trial continues to track towards a topline data readout in the third quarter of 2026.\nThe global total addressable market (TAM) for PWS, according to William Blair’s estimates, is roughly $10 billion, and there is currently only one approved treatment.\nAnalyst Andy Hsieh says this opportunity alone justifies its valuation framework.\nAardvark is also developing ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor, and conducting two separate trials to address some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions.\nARD-201’s TAM could reach at least $100 billion, and serve as an oral and more tolerable alternative to GLP-1RAs, and both maintenance and induction settings are being investigated, offering investors multiple shots on goal.\nWilliam Blair says there is an appreciable disconnect between the current market value of $304 million and the potential of lead program ARD-101.\nAardvark had cash, cash equivalents, and short-term investments of $126.4 million, which will be sufficient to fund projected operations into 2027.\nAARD Price Action: Aardvark Therapeutics shares were down 6.28% at $14.63 at the time of publication on Friday, according to Benzinga Pro data.\nRead Next:\nPhoto by shisu_ka via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591686624","isCrawlerRequest":true}